Incretin mimetics (GLP-1, GIP, and glucagon receptor agonists) demonstrate neurotrophic and neuroprotective effects in TBI cell and animal models, with established safety profiles from diabetes use making them ideal candidates for rapid clinical evaluation.
70M annual TBI cases, few treatmentsIncretin drugs already proven safe in millions of diabetes patients could be rapidly evaluated for the 70 million annual traumatic brain injuries worldwide
What the researchers found
Incretins reduce neuroinflammation, protect BBB, and promote neuronal survival in TBI models. 70 million annual TBI cases (81% concussions). Already safe in diabetes patients. Ideal for rapid clinical trial evaluation.
Why it matters
TBI has essentially no disease-modifying treatments. Repurposing already-approved GLP-1 drugs could provide a neuroprotective therapy much faster than developing new drugs from scratch.
How the study worked
Narrative review of cellular and animal TBI studies plus limited clinical evidence for incretin-based neuroprotection.
What this study cannot tell us
Mostly preclinical evidence. Limited clinical TBI data. Optimal dosing, timing post-injury, and patient selection unknown. BBB penetration of some incretins may be limited.
How to read the evidence
Narrative review of preclinical and limited clinical evidence. Strong biological rationale supported by safety data from other indications.
When this study was published
Published in 2025.
The bigger picture
Incretin-based neuroprotection is gaining momentum across multiple neurological conditions (Parkinson's, Alzheimer's, MS, and now TBI). The consistent neuroprotective signal across different disease models suggests a fundamental mechanism worth exploiting.
Questions still open
- What is the optimal time window for incretin administration after TBI?
- Which incretin agent has the best BBB penetration for acute TBI?
- Could military and sports medicine populations benefit most from early trials?
Common questions
Could diabetes drugs help with concussions?
Why are there so few treatments for brain injuries?
Read the original research
Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review.
International journal of molecular sciences, 27(1)
Citation
Sipos, Samuel; Jerkic, Mirjana; Rotstein, Ori D; Schweizer, Tom A. (2025). Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review.. International journal of molecular sciences, 27(1). https://doi.org/10.3390/ijms27010045